Epidemic Investigation of Benign Prostatic Obstruction with Coexisting Overactive Bladder in Shanghai Pudong New Area and Its Impact on the Health-related Quality of Life

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2019 Sep 5

PMID 31481034

Citations 1

Authors

Qing-Tong Yi

Min Gong

Chu-Hong Chen

Wei Hu

Ru-Jian Zhu

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to investigate the prevalence, relative risk factors, and the impact on the health-related quality of life (HRQoL) of benign prostatic obstruction (BPO) with coexisting overactive bladder (OAB) in men aged over 50 and living in Shanghai Pudong New Area.

Methods: Using a multi-stage sampling and descriptive epidemiological method, 1632 men were selected from among the general population. Participants completed an evaluation of lower urinary tracts symptoms (LUTS), including international prostate symptom score (IPSS) and quality of life (QoL) questionnaires. Erectile function was assessed using the International Index of Erectile Function-5 (IIEF-5) questionnaire. In addition, the Overactive Bladder Symptom Score (OABSS) and King's health questionnaire (KHQ) were used to assess the impact of BPO with coexisting OAB on the HRQoL. Maximum flow rate (Q), postvoid residual urine volume (PVR) and prostate-specific antigen (PSA) were also recorded.

Results: A total of 1476 men with complete data were analyzed. The overall prevalence of BPO with coexisting OAB was 39.6%. Age and prostate volume were associated risk factors for BPO with coexisting OAB. In addition, BPO with coexisting OAB negatively impacted the HRQoL, with increased IPSS, QoL, OABSS, and KHQ scores and decreased IIEF-5 scores compared to that in patients with BPO without OAB.

Conclusions: Q, PVR and serum PSA did not predict whether the patients had a combined BPO + OAB or not. The prostate volume and age were associated risk factors for BPO with coexisting OAB. BPO is a progressive disease and may be one of the risk factors for OAB.

Citing Articles

A Comparative Study on the Clinical Outcomes of Bipolar Radiofrequency Thermotherapy Versus Transurethral Resection of the Prostate in Storage Symptoms Associated With Benign Prostatic Obstruction.

Yuce A, Benli E, Basar D, Yazici I, Cirakoglu A, Nalbant I Int Neurourol J. 2025; 28(4):285-293.

PMID: 39765341 PMC: 11710952. DOI: 10.5213/inj.2346184.092.

Inhibition of DNA methylation during chronic obstructive bladder disease (COBD) improves function, pathology and expression.

Sidler M, Aitken K, Jiang J, Yadav P, Lloyd E, Ibrahim M Sci Rep. 2021; 11(1):17307.

PMID: 34453065 PMC: 8397724. DOI: 10.1038/s41598-021-96155-4.

References

Knutson T, Edlund C, Fall M, Dahlstrand C . BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma. Neurourol Urodyn. 2001; 20(3):237-47. DOI: 10.1002/nau.1001. View

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2):167-78. DOI: 10.1002/nau.10052. View

Roehrborn C, McConnell J, Saltzman B, Bergner D, Gray T, Narayan P . Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol. 2002; 42(1):1-6. DOI: 10.1016/s0302-2838(02)00210-5. View

Hirayama A, Samma S, Fujimoto K, Yamaguchi A, Akiyama T, Fukui Y . Comparison of parameters to determine the cause of urinary disturbance in men with prostate volume less than 20 milliliters. Int J Urol. 2002; 9(10):554-9; discussion 560. DOI: 10.1046/j.1442-2042.2002.00524.x. View

Wein A, Rovner E . Definition and epidemiology of overactive bladder. Urology. 2002; 60(5 Suppl 1):7-12; discussion 12. DOI: 10.1016/s0090-4295(02)01784-3. View

Chia S, Heng C, Chan S, Foo K . Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 2003; 91(4):371-4. DOI: 10.1046/j.1464-410x.2003.04088.x. View

Barry M, Fowler Jr F, OLeary M, Bruskewitz R, HOLTGREWE H, MEBUST W . The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148(5):1549-57; discussion 1564. DOI: 10.1016/s0022-5347(17)36966-5. View

Reese P, Pleil A, Okano G, Kelleher C . Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res. 2003; 12(4):427-42. DOI: 10.1023/a:1023422208910. View

McConnell J, Roehrborn C, Bautista O, Andriole Jr G, Dixon C, Kusek J . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349(25):2387-98. DOI: 10.1056/NEJMoa030656. View

10.

Moorthy P, Lapitan M, Quek P, Lim P . Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int. 2004; 93(4):528-31. DOI: 10.1111/j.1464-410x.2003.04682.x. View

11.

Doward L, McKenna S . Defining patient-reported outcomes. Value Health. 2004; 7 Suppl 1:S4-8. DOI: 10.1111/j.1524-4733.2004.7s102.x. View

12.

Lee J, Kim H, Lee S, Koh J, Suh H, Chancellor M . Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94(6):817-20. DOI: 10.1111/j.1464-410X.2004.05039.x. View

13.

Lowe F, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F . Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis. 2005; 8(3):206-9. DOI: 10.1038/sj.pcan.4500806. View

14.

Li M, Garcia L, Rosen R . Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005; 96(9):1339-54. DOI: 10.1111/j.1464-410X.2005.05831.x. View

15.

Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M . Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006; 68(2):318-23. DOI: 10.1016/j.urology.2006.02.042. View

16.

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View

17.

Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6):1306-14. DOI: 10.1016/j.eururo.2006.09.019. View

18.

Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S . Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology. 2007; 70(6):1096-9. DOI: 10.1016/j.urology.2007.08.008. View

19.

Hofner K, Burkart M, Jacob G, Jonas U . Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol. 2009; 28(3):353-7. DOI: 10.1007/s00345-009-0460-7. View

20.

Foo K . Decision making in the management of benign prostatic enlargement and the role of transabdominal ultrasound. Int J Urol. 2010; 17(12):974-9. DOI: 10.1111/j.1442-2042.2010.02668.x. View